Risk of GC-related and GC-unrelated organ damage development during 2-year follow-up across different patterns of GC tapering in 127 patients with newly diagnosed SLE starting concomitant hydroxychloroquine or immunosuppressants
| GC-related damage | GC-unrelated damage | |||||||
| Crude OR (95% CI) | P | Adj OR* (95% CI) | P | Crude OR (95% CI) | P | Adj OR* (95% CI) | P | |
| Tapering PDN <5 mg/day | Ref. | Ref. | Ref. | Ref. | ||||
| Fail to taper PDN <5 mg/day | 0.86 (0.21 to 3.22) | 0.824 | 0.98 (0.20 to 4.45) | 0.975 | 0.69 (0.25 to 1.81) | 0.457 | 1.02 (0.32 to 3.24) | 0.967 |
| Never tapered PDN <5 mg/day | 4.54 (1.47 to 15.10) | 0.010 | 5.90 (1.53 to 27.0) | 0.014 | 1.89 (0.71 to 5.03) | 0.197 | 2.28 (0.70 to 7.57) | 0.168 |
*Adjusted for age, gender, ECLAM score, baseline SDI and PDN daily dose.
ECLAM, European Consensus Lupus Activity Measurement; GC, glucocorticoid; PDN, prednisone; SLE, systemic lupus erythematosus.